Drug prices jump 5.7% in Q1; Hep C drugmakers scramble to cut weeks off treatment;

> Branded drug prices jumped 5.7% during the first quarter of 2015, with specialty meds increasing by 2.5%; the biggest increases came in infertility, menopause and hormone deficiency treatments, including generics. Release

> Hepatitis C drugmakers, including Gilead Sciences ($GILD), are racing to cut down on treatment times, hoping to gain an edge as new competitors hit the market. Report

> Generic drug use in Japan is on its way up, but not as much as expected, because consumers are loyal to their branded meds. Report

> MannKind ($MNKD) plans to manufacture a 12-unit cartridge strength of its inhaled insulin Afrezza, marketed by Sanofi ($SNY). Report

> A melanoma-fighting combo of Bristol-Myers Squibb's ($BMY) Yervoy and Opdivo caused one woman's tumor to "dissolve" so rapidly, it prompted a case study in the latest New England Journal of Medicine. Report

And Finally... BioDigital, which developed a "Google Earth" for the human body, won a 2015 Webby award; the company sees pharma companies as potential clients. Release

Suggested Articles

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.